Quince Therapeutics, Inc.
QNCX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.07 | -0.05 | -0.01 | 0.02 |
| FCF Yield | -6.74% | -16.68% | -9.50% | -21.81% |
| EV / EBITDA | -4.87 | -4.47 | -8.87 | -5.47 |
| Quality | ||||
| ROIC | -9.05% | -14.97% | -11.19% | -4.85% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.71 | 0.64 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 46.72% | -26.86% | -5.19% | 16.77% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | -0.54 | -0.85 | -1.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,523.14 | -8,460.00 | -2,637.86 | -1,697.44 |